VA Greater LA Healthcare System

Los Angeles, California 90095

3 studies enrolling now · 7 studies all time

What they study most

Oligometastatic Prostate Cancer (OMPC), PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy, Prostate Cancer, Prostatic Neoplasms, Pulmonary Arterial Hypertension, Pulmonary Disease, Relapsing Multiple Sclerosis

Studies at this site

• An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC. — Recruiting now
• A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC — Recruiting now
• Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy — Recruiting now
• Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) — Running, not enrolling
• An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) — Running, not enrolling
• DECAMP 1 PLUS: Prediction of Lung Cancer Using Noninvasive Biomarkers — Running, not enrolling
• Study of Cicletanine for Pulmonary Arterial Hypertension (PAH) — Stopped early